Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections

Iwata Takehiro, Sadahira Takuya, Maruyama Yuki, Sekito Takanori, Yoshinaga Kasumi, Watari Shogo, Nagao Kentaro, Kawada Tatsushi, Tominaga Yusuke, Nishimura Shingo, Takamoto Atsushi, Sako Tomoko, Edamura Kohei, Kobayashi Yasuyuki, Araki Motoo, Ishii Ayano, Watanabe Masami, Watanabe Toyohiko, Nasu Yasutomo, Wada Koichiro

doi:10.18926/amo/62820

この論文をさがす

説明

The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.

収録刊行物

Acta Medica Okayama

Acta Medica Okayama 75 (6), 763-766, 2021-12

Okayama University Medical School

キーワード

詳細情報詳細情報について

CRID: 1390572176828763648

NII論文ID: 120007180272

NII書誌ID: AA00508441

ISSN: 0386300X

DOI: 10.18926/amo/62820

PubMed: 34955548

Web Site: https://ousar.lib.okayama-u.ac.jp/62820; https://search.jamas.or.jp/link/ui/2022320083

本文言語コード: en

資料種別: journal article

データソース種別

JaLC
IRDB
CiNii Articles
OpenAIRE

書き出し

問題の指摘